Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 5/20 | 0.79 |
| ▸ | TYMS | P04818 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 5/20 | 0.55 |
| ▸ | GART | P22102 | 2/20 | 0.52 |
| ▸ | ATIC | P31939 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423667 | 1.00 | AKR1B1 (0.79) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL15094347 | 0.93 | AKR1B1 (0.81) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL30174303 | 0.93 | AKR1B1 (0.81) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL28226859 | 0.92 | AKR1B1 (0.80) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL11897941 | 0.91 | AKR1B1 (0.79) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL30634933 | 0.91 | AKR1B1 (0.79) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL6679712 | 0.91 | AKR1B1 (0.77) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL14323639 | 0.91 | AKR1B1 (0.77) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL15530422 | 0.91 | AKR1B1 (0.77) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL8044594 | 0.91 | AKR1B1 (0.77) | AKR1B1TYMSKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109432451-A | A kind of preparation method for extra small double targeting bimodal magnetic resonance contrast agents that kidney is removed | 南京大学 | 2019-03-08 | — | — | CN | claimed |
| US-12458701-B2 | Bis (hydroxy benzylidene) cyclic ketone based tetra-aza corand | DESAI ARPITA (IN) | 2025-11-04 | — | — | US | disclosed |
| EP-3352796-B1 | DRUG FORMULATION BASED ON PARTICULATES COMPRISING POLYSACCHARIDE-VITAMIN CONJUGATE | U S TIANYOU CAPITAL CORP (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119455006-A | Targeting drug-loaded nano-particle with multiple responsivity and preparation method thereof | 四川大学华西医院 | 2025-02-18 | — | — | CN | disclosed |
| CN-117321078-A | Administration for combination therapy with anti-CD 20/anti-CD 3 bispecific antibody and anti-CD 79B antibody drug conjugates | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116462705-A | Folic acid phosphating derivative and preparation method and application thereof | 浙江圣达生物药业股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230226194-A1 | NOVEL BIS (HYDROXY BENZYLIDENE) CYCLIC KETONE BASED TETRA-AZA CORAND | DESAI ARPITA (IN) | 2023-07-20 | — | — | US | disclosed |
| WO-2022074673-A1 | NOVEL BIS (HYDROXY BENZYLIDENE) CYCLIC KETONE BASED TETRA-AZA CORAND | DESAI DR ARPITA S (IN) | 2022-04-14 | — | — | WO | disclosed |
| CN-108135917-B | Pharmaceutical formulations based on particles comprising polysaccharide-vitamin conjugates | ZY医疗 | 2021-07-09 | — | — | CN | disclosed |
| US-10994024-B2 | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate | ZY Therapeutics, Inc. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20110110854-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2291678-A2 | IMPROVED METHODS AND COMPOSITIONS FOR F-18 LABELING OF PROTEINS, PEPTIDES AND OTHER MOLECULES | Immunomedics, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-2200657-A1 | IMPROVED METHODS AND COMPOSITIONS FOR F-18 LABELING OF PROTEINS, PEPTIDES AND OTHER MOLECULES | Immunomedics, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090299033-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009135015-A2 | IMPROVED METHODS AND COMPOSITIONS FOR F-18 LABELING OF PROTEINS, PEPTIDES AND OTHER MOLECULES | IMMUNOMEDICS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090246130-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7563433-B2 | Use in positron emission tomography for example or tissue targeted therapy; forming a F18 metal complex, and attaching the F-18 metal complex to the molecule such as peptide or antibody; improved biological half life | IMMUNOMEDICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| WO-2009079024-A1 | IMPROVED METHODS AND COMPOSITIONS FOR F-18 LABELING OF PROTEINS, PEPTIDES AND OTHER MOLECULES | IMMUNOMEDICS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090155166-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20080253964-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10994024-B2 | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate | FOLR1, FOLR2, CD44 | AKR1B1 2751/4885TYMS 71/4885KDM4E 3468/4885 |
| US-12458701-B2 | Bis (hydroxy benzylidene) cyclic ketone based tetra-aza corand | HDAC6, TBCA, TBC1D15 | AKR1B1 85/4885TYMS 412/4885KDM4E 239/4885 |
| US-20110110854-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, F13A1, FCGRT | AKR1B1 4102/4885TYMS 3955/4885KDM4E 3547/4885 |
| US-20090246130-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, TFRC, F13A1 | AKR1B1 4250/4885TYMS 4267/4885KDM4E 3900/4885 |
| US-20230226194-A1 | NOVEL BIS (HYDROXY BENZYLIDENE) CYCLIC KETONE BASED TETRA-AZA CORAND | HDAC6, TBCA, TBC1D15 | AKR1B1 91/4885TYMS 394/4885KDM4E 239/4885 |
| US-20090155166-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | S100A8, TFRC, F13A1 | AKR1B1 4393/4885TYMS 3887/4885KDM4E 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.